Developer docs
API playgroundTry for free, no card

Search company profiles

Sagimet Biosciences

Full company profile

uuid000065x

Namestring
Sagimet Biosciences
Legal namestring
Sagimet Biosciences Inc.
Websiteurl
sagimet.com
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of selective fatty acid synthase (FASN) inhibitors for diseases driven by dysregulated lipid metabolism. Its lead candidate, denifanstat (ASC40), is an oral once-daily FASN inhibitor that binds a non-enzymatic region of the FASN protein and has been evaluated in more than 1,200 subjects across moderate-to-severe acne, MASH (F2/F3 and F4), and FASN-dependent solid tumors. The pipeline also includes TVB-3567 (Phase 1 in acne), a preclinical topical FASN inhibitor, and a denifanstat + resmetirom fixed-dose combination in development for MASH.

The company's go-to-market is bifurcated by geography: in Greater China, partner Ascletis Bioscience runs development and commercialization under a licensing arrangement (NDA accepted by China's NMPA in December 2025), generating milestone and future royalty income for Sagimet. In the United States, Sagimet plans to file an IND in mid-2026 and initiate a registrational Phase 3 acne trial in H2 2026, with downstream distribution intended through standard pharmaceutical/prescription channels. Sagimet has 11-50 employees, is headquartered in San Mateo, California, completed its NASDAQ IPO (SGMT) in January 2024 raising ~$112.5M, and closed a $175M follow-on in April 2026 to fund operations through 2028.

Sagimet is pre-revenue and unprofitable, posting a $51.0M net loss in 2025 (vs. $45.6M in 2024) against $113.1M of cash at year-end 2025; consensus equity research from 11 analysts carries a "Moderate Buy" rating with a ~$26.25 average price target, and institutional investors own approximately 87.86% of the stock. The business model is therefore classic clinical-stage biotech: capital is raised in the public markets, deployed into Phase 3 development, and the company is positioned for either an asset sale, partnership, or independent commercialization if US approval is secured.

Short descriptiontext

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing oral FASN inhibitors, led by denifanstat for moderate-to-severe acne, MASH, and FASN-dependent solid tumors, with Ascletis commercializing in Greater China and direct US development planned via a Phase 3 acne trial in H2 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFoster City, United States
HQ citystring
Foster City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fatty acid synthase inhibitors, biopharmaceutical drug development, metabolic disease therapeutics, MASH treatment development, clinical-stage biopharmaceutical
Industry2 codes
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage biopharmaceutical therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biopharma. Plans to commercialize denifanstat and pipeline products upon regulatory approval. Will distribute through pharmaceutical prescription channels.

sagimet.com
2Licensing and Partnership Revenue
TypeLicensing Royalties
Description

License partner Ascletis conducts Phase 3 trials in China; Sagimet receives milestone payments from partnership. Ascletis reported positive Phase 3 data and China's NMPA accepted NDA for denifanstat in acne.

stocktitan.net
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing selective fatty acid synthase (FASN) inhibitors to treat diseases driven by dysfunctional metabolic and fibrotic pathways caused by overproduction of palmitate. Its lead product candidate, denifanstat, is an oral once-daily selective FASN inhibitor being developed for moderate-to-severe acne, MASH, and certain FASN-dependent solid tumors. The company is also advancing TVB-3567, a topical FASN inhibitor formulation, and a fixed-dose combination of denifanstat with resmetirom for MASH.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of novel fatty acid synthase (FASN) inhibitors. The core product is denifanstat (ASC40), an oral, once-daily selective FASN inhibitor with clinical data across multiple disease states including metabolic dysfunction-associated steatohepatitis (MASH), acne vulgaris, and certain FASN-dependent solid tumors. Additional pipeline products include TVB-3567 (a second FASN inhibitor in Phase 1 for acne) and a topical FASN inhibitor formulation in preclinical development. The company is also developing a fixed-dose combination of denifanstat with resmetirom for MASH treatment.

Product and service4 records
1Denifanstat (ASC40 / TVB-2640)
CategoryCore product candidate
Description

Oral, once-daily selective fatty acid synthase (FASN) inhibitor that binds to a unique non-active site on the FASN protein. Studied in more than 1,200 subjects across clinical trials in moderate-to-severe acne vulgaris, MASH, and certain FASN-dependent solid tumors, with positive Phase 2b FASCINATE-2 data in MASH and positive Phase 3 acne data from partner Ascletis in China.

2TVB-3567
CategoryPipeline product candidate
Description

Potent and selective small-molecule FASN inhibitor in clinical development for acne, showing potent inhibition of palmitate synthesis in human, rat, mouse, and dog cell lines. IND-enabling GLP toxicology studies completed; first-in-human Phase 1 initiated.

3FASN Inhibitor Topical Formulation
CategoryPipeline product candidate
Description

Topical formulation of a FASN inhibitor in preclinical development for dermatology applications. IND-enabling studies completed; evaluation of IND filing timing ongoing.

4Denifanstat + Resmetirom Fixed-Dose Combination
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Eduardo Bruno Martins
Strategic tierMinorTypeOthersAnnounced on2026-04-20
Description

Eduardo Bruno Martins retired as Chief Medical Officer on April 20, 2026, succeeded by Andreas Grauer.

stocktitan.net
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-17
Description

Global license agreement for innovative forms of resmetirom active pharmaceutical ingredients for Sagimet's fixed-dose combination program combining resmetirom with denifanstat for MASH treatment.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-01-01
Description

License partner conducting Phase 3 clinical trials for denifanstat in China. Ascletis reported positive Phase 3 results in acne and China's NMPA accepted the NDA for denifanstat. Sagimet receives milestone payments. Trials conducted in China by Ascletis, who has licensed development and commercialization rights to all indications in Greater China.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct MASH peer developing lanifibranor (pan-PPAR agonist), with Phase 3 NATiV3 actively enrolling. Similar profile as a clinical-stage European biotech focused on F2/F3 MASH with regulatory pathway to approval.

TypeDirect peer
Description

Direct peer in MASH with FDA-approved resmetirom (Rezdiffra), the only currently approved MASH therapy. Sagimet is also developing a fixed-dose combination with resmetirom, making Madrigal both a competitor and a partner for combination development.

TypeDirect peer
Description

Direct MASH peer developing efruxifermin (FGF21 analog) with strong Phase 2b HARMONY data and Phase 3 SYNCHRONY program underway. Comparable clinical-stage biopharma competing in the same MASH regulatory space.

TypeDirect peer
Description

Direct MASH peer developing pegozafermin (FGF21 analog) with positive Phase 2b ENLIGHTEN data and Phase 3 HARMONY 3 program in progress. Similar sized clinical-stage biotech pursuing metabolic liver disease with novel mechanism.

TypeDirect peer
Description

Direct MASH and metabolic peer with VK2809 (oral THR-β agonist) Phase 2b VOYAGE data and broader metabolic/obesity pipeline. Comparable clinical-stage biotech with multiple indications and strong investor attention.

TypeDirect peer
Description

License partner developing and commercializing denifanstat in Greater China, and a direct peer in MASH and acne with overlapping pipeline candidates. Strongly comparable business with both commercial and clinical-stage assets in the same indications.

TypeDirect peer
Description

Direct MASH peer with TERN-501 (oral THR-β agonist) and TERN-601 oral GLP-1 in development. Similar clinical-stage biotech profile targeting MASH with novel oral mechanism.

TypeBroad incumbent
Description

Liver disease peer that developed seladelpar (PPARδ agonist) for primary biliary cholangitis, acquired by Gilead for $4.3B in March 2024. Demonstrates large-pharma appetite for clinical-stage liver/MASH assets and a relevant comparable for Sagimet's MASH franchise value.

TypeEmerging player
Description

Smaller clinical-stage peer developing aramchol meglumine for MASH, with Phase 3 ARMOR study. Smaller market cap comparable in indication overlap, providing a lower-scale proxy for FASN inhibitor competitive dynamics in MASH.

TypeBroad incumbent
Description

Historical NASH/MASH peer (obeticholic acid) that received FDA CRL and underwent significant restructuring. Provides important cautionary comparable on MASH regulatory execution risk and the capital intensity of bringing a liver drug to market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors26 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sagimet Biosciences

Clinical-stage biopharmaceutical therapeuticssagimet.com

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing oral FASN inhibitors, led by denifanstat for moderate-to-severe acne, MASH, and FASN-dependent solid tumors, with Ascletis commercializing in Greater China and direct US development planned via a Phase 3 acne trial in H2 2026.

What Sagimet Biosciences does

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of selective fatty acid synthase (FASN) inhibitors for diseases driven by dysregulated lipid metabolism. Its lead candidate, denifanstat (ASC40), is an oral once-daily FASN inhibitor that binds a non-enzymatic region of the FASN protein and has been evaluated in more than 1,200 subjects across moderate-to-severe acne, MASH (F2/F3 and F4), and FASN-dependent solid tumors. The pipeline also includes TVB-3567 (Phase 1 in acne), a preclinical topical FASN inhibitor, and a denifanstat + resmetirom fixed-dose combination in development for MASH.

The company's go-to-market is bifurcated by geography: in Greater China, partner Ascletis Bioscience runs development and commercialization under a licensing arrangement (NDA accepted by China's NMPA in December 2025), generating milestone and future royalty income for Sagimet. In the United States, Sagimet plans to file an IND in mid-2026 and initiate a registrational Phase 3 acne trial in H2 2026, with downstream distribution intended through standard pharmaceutical/prescription channels. Sagimet has 11-50 employees, is headquartered in San Mateo, California, completed its NASDAQ IPO (SGMT) in January 2024 raising ~$112.5M, and closed a $175M follow-on in April 2026 to fund operations through 2028.

Sagimet is pre-revenue and unprofitable, posting a $51.0M net loss in 2025 (vs. $45.6M in 2024) against $113.1M of cash at year-end 2025; consensus equity research from 11 analysts carries a "Moderate Buy" rating with a ~$26.25 average price target, and institutional investors own approximately 87.86% of the stock. The business model is therefore classic clinical-stage biotech: capital is raised in the public markets, deployed into Phase 3 development, and the company is positioned for either an asset sale, partnership, or independent commercialization if US approval is secured.

Sagimet Biosciences firmographics

Firmographics
Name
Sagimet Biosciences
Legal name
Sagimet Biosciences Inc.
Website
https://sagimet.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing oral FASN inhibitors, led by denifanstat for moderate-to-severe acne, MASH, and FASN-dependent solid tumors, with Ascletis commercializing in Greater China and direct US development planned via a Phase 3 acne trial in H2 2026.
Ownership category
akta.pro rank

Sagimet Biosciences industry classification

Industry
Product category
Clinical-stage biopharmaceutical therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Fatty acid synthase inhibitors
  • Biopharmaceutical drug development
  • Metabolic disease therapeutics
  • MASH treatment development
  • Clinical-stage biopharmaceutical

Where Sagimet Biosciences is headquartered

Location

Headquarters

HQ city
Foster City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sagimet Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharma. Plans to commercialize denifanstat and pipeline products upon regulatory approval. Will distribute through pharmaceutical prescription channels.
  2. Licensing and Partnership Revenue: License partner Ascletis conducts Phase 3 trials in China; Sagimet receives milestone payments from partnership. Ascletis reported positive Phase 3 data and China's NMPA accepted NDA for denifanstat in acne.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Sagimet Biosciences product offering

Product offering

Core offering

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing selective fatty acid synthase (FASN) inhibitors to treat diseases driven by dysfunctional metabolic and fibrotic pathways caused by overproduction of palmitate. Its lead product candidate, denifanstat, is an oral once-daily selective FASN inhibitor being developed for moderate-to-severe acne, MASH, and certain FASN-dependent solid tumors. The company is also advancing TVB-3567, a topical FASN inhibitor formulation, and a fixed-dose combination of denifanstat with resmetirom for MASH.

Product overview

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of novel fatty acid synthase (FASN) inhibitors. The core product is denifanstat (ASC40), an oral, once-daily selective FASN inhibitor with clinical data across multiple disease states including metabolic dysfunction-associated steatohepatitis (MASH), acne vulgaris, and certain FASN-dependent solid tumors. Additional pipeline products include TVB-3567 (a second FASN inhibitor in Phase 1 for acne) and a topical FASN inhibitor formulation in preclinical development. The company is also developing a fixed-dose combination of denifanstat with resmetirom for MASH treatment.

Differentiator

Problem solved

Functional benefit

Products and services

  • Denifanstat (ASC40 / TVB-2640) Oral, once-daily selective fatty acid synthase (FASN) inhibitor that binds to a unique non-active site on the FASN protein. Studied in more than 1,200 subjects across clinical trials in moderate-to-severe acne vulgaris, MASH, and certain FASN-dependent solid tumors, with positive Phase 2b FASCINATE-2 data in MASH and positive Phase 3 acne data from partner Ascletis in China.
  • TVB-3567 Potent and selective small-molecule FASN inhibitor in clinical development for acne, showing potent inhibition of palmitate synthesis in human, rat, mouse, and dog cell lines. IND-enabling GLP toxicology studies completed; first-in-human Phase 1 initiated.
  • FASN Inhibitor Topical Formulation Topical formulation of a FASN inhibitor in preclinical development for dermatology applications. IND-enabling studies completed; evaluation of IND filing timing ongoing.
  • Denifanstat + Resmetirom Fixed-Dose Combination

Companies that use Sagimet Biosciences

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Sagimet Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sagimet Biosciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Eduardo Bruno MartinsminorOthers · 20 April 2026Eduardo Bruno Martins retired as Chief Medical Officer on April 20, 2026, succeeded by Andreas Grauer.
  • TAPI (Technology & API Services)coreStrategic or Co-development Partner · 17 December 2025Global license agreement for innovative forms of resmetirom active pharmaceutical ingredients for Sagimet's fixed-dose combination program combining resmetirom with denifanstat for MASH treatment.
  • Ascletis Bioscience Co. Ltd.coreOEM/ Whitelabel/ Licensing Partner · 1 January 2023License partner conducting Phase 3 clinical trials for denifanstat in China. Ascletis reported positive Phase 3 results in acne and China's NMPA accepted the NDA for denifanstat. Sagimet receives milestone payments. Trials conducted in China by Ascletis, who has licensed development and commercialization rights to all indications in Greater China.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Sagimet Biosciences competitors and assessment

Company assessment

Direct peers

  • Inventiva: Direct MASH peer developing lanifibranor (pan-PPAR agonist), with Phase 3 NATiV3 actively enrolling. Similar profile as a clinical-stage European biotech focused on F2/F3 MASH with regulatory pathway to approval.
  • Madrigal Pharmaceuticals: Direct peer in MASH with FDA-approved resmetirom (Rezdiffra), the only currently approved MASH therapy. Sagimet is also developing a fixed-dose combination with resmetirom, making Madrigal both a competitor and a partner for combination development.
  • Akero Therapeutics: Direct MASH peer developing efruxifermin (FGF21 analog) with strong Phase 2b HARMONY data and Phase 3 SYNCHRONY program underway. Comparable clinical-stage biopharma competing in the same MASH regulatory space.
  • 89bio: Direct MASH peer developing pegozafermin (FGF21 analog) with positive Phase 2b ENLIGHTEN data and Phase 3 HARMONY 3 program in progress. Similar sized clinical-stage biotech pursuing metabolic liver disease with novel mechanism.
  • Viking Therapeutics: Direct MASH and metabolic peer with VK2809 (oral THR-β agonist) Phase 2b VOYAGE data and broader metabolic/obesity pipeline. Comparable clinical-stage biotech with multiple indications and strong investor attention.
  • Ascletis Bioscience: License partner developing and commercializing denifanstat in Greater China, and a direct peer in MASH and acne with overlapping pipeline candidates. Strongly comparable business with both commercial and clinical-stage assets in the same indications.
  • Terns Pharmaceuticals: Direct MASH peer with TERN-501 (oral THR-β agonist) and TERN-601 oral GLP-1 in development. Similar clinical-stage biotech profile targeting MASH with novel oral mechanism.

Broad incumbents

  • CymaBay Therapeutics: Liver disease peer that developed seladelpar (PPARδ agonist) for primary biliary cholangitis, acquired by Gilead for $4.3B in March 2024. Demonstrates large-pharma appetite for clinical-stage liver/MASH assets and a relevant comparable for Sagimet's MASH franchise value.
  • Intercept Pharmaceuticals: Historical NASH/MASH peer (obeticholic acid) that received FDA CRL and underwent significant restructuring. Provides important cautionary comparable on MASH regulatory execution risk and the capital intensity of bringing a liver drug to market.

Emerging players

  • Galmed Pharmaceuticals: Smaller clinical-stage peer developing aramchol meglumine for MASH, with Phase 3 ARMOR study. Smaller market cap comparable in indication overlap, providing a lower-scale proxy for FASN inhibitor competitive dynamics in MASH.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Sagimet Biosciences social profiles

Digital presence

Sagimet Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sagimet Biosciences leadership team

Management profile

Number of profiles

Profiles12 records

Sagimet Biosciences funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sagimet Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sagimet Biosciences

What does Sagimet Biosciences do?

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing selective fatty acid synthase (FASN) inhibitors to treat diseases driven by dysfunctional metabolic and fibrotic pathways caused by overproduction of palmitate. Its lead product candidate, denifanstat, is an oral once-daily selective FASN inhibitor being developed for moderate-to-severe acne, MASH, and certain FASN-dependent solid tumors. The company is also advancing TVB-3567, a topical FASN inhibitor formulation, and a fixed-dose combination of denifanstat with resmetirom for MASH.

Is Sagimet Biosciences a public or private company?

Sagimet Biosciences is a public company. It is classified as public and is currently operating.

When was Sagimet Biosciences founded?

Sagimet Biosciences was founded in 2006. It employs 11 to 50 people.

Where is Sagimet Biosciences based?

Sagimet Biosciences is headquartered in Foster City, United States, in the North America region.

How does Sagimet Biosciences make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Revenue.

Who are Sagimet Biosciences's main competitors?

Direct peers on record are Inventiva, Madrigal Pharmaceuticals, Akero Therapeutics, 89bio, Viking Therapeutics, Ascletis Bioscience and Terns Pharmaceuticals. Broad incumbents are CymaBay Therapeutics and Intercept Pharmaceuticals. Galmed Pharmaceuticals is listed as an emerging player.

Does Sagimet Biosciences have an API?

No public API is recorded for Sagimet Biosciences.

What industry is Sagimet Biosciences in?

Sagimet Biosciences's product category is Clinical-stage biopharmaceutical therapeutics. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldSagimet Biosciences Inc. (NASDAQ:SGMT) Stock Has Average Price Target of $26.07Sagimet Biosciences received a consensus 'Moderate Buy' rating from 11 analysts, with an average price target of $26.07. The stock opened at $10.13, and institutional investors own 87.86% of shares. The company reported a quarterly loss of $0.31 per share, missing the consensus estimate.MarketScreenerCertain Restricted Stock Units of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2026.Sagimet Biosciences' restricted stock units are subject to a 45-day lock-up period from the prospectus supplement date. During this period, the company, its officers, directors, and certain stockholders may not sell, pledge, or dispose of securities without underwriter consent, subject to customary exceptions.MarketScreenerCertain Options of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2026.Certain options of Sagimet Biosciences are subject to a 45-day lock-up agreement ending on November 15, 2026. The lock-up covers the company, its executives, directors, and certain stockholders, prohibiting them from selling or disposing of securities without underwriter consent.MarketScreenerCertain Series B Common Stock of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2026.Certain Series B common stock of Sagimet Biosciences is subject to a 45-day lock-up agreement ending on 15-NOV-2026. The lock-up covers the company, its officers, directors, and certain stockholders, prohibiting them from selling, pledging, or disposing of the securities without underwriter consent.TradingViewCanaccord Genuity maintains Sagimet Biosciences at BuyCanaccord Genuity maintained Sagimet Biosciences at Buy. The rating was maintained, with no price target or additional details provided in the body.TradingViewSagimet Biosciences Inc. - Series A Stock 12‑Month Price Target Cut to $27.46, Implies 141% UpsideAnalysts' average price target for Sagimet Biosciences Inc. fell from $27.92 to $27.46, implying about 141% upside from the Nov. 11 close. The consensus remains Buy across 14 analysts, with 13 Buys, 0 Holds, and 1 Sell.Business & FinancialSagimet Biosciences Reports Third Quarter 2026 Financial Results And Provides Corporate UpdatesSagimet Biosciences reported Q3 2026 financial results and corporate updates, including the initiation of its U.S. AURORA Phase 3 trial for denifanstat in moderate to severe acne. The company raised $115 million in equity, leaving pro forma cash of $356 million to fund operations through mid-2029. Topline data from AURORA is expected in the second half of 2027.GlobeNewswireSagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesSagimet Biosciences reported Q3 2026 financial results and corporate updates, including the initiation of its U.S. AURORA Phase 3 clinical trial for denifanstat in moderate to severe acne. The company raised $115 million in equity financing, leaving pro forma cash of $356 million to fund operations through mid-2029. Topline data from AURORA is expected in the second half of 2027.YahooAscletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe AcneSagimet Biosciences dosed the first patient in AURORA, a pivotal Phase III U.S. trial of denifanstat (ASC40) for moderate to severe acne. The trial enrolls about 800 patients, including 450 adolescents, and builds on positive Phase III results from Ascletis. If approved, the drug could address a need among approximately 10 million Americans.PR Newswire APACAscletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe AcneSagimet Biosciences dosed the first patient in AURORA, a pivotal Phase III U.S. trial of denifanstat (ASC40) for moderate to severe acne. The trial enrolls about 800 patients, including 450 adolescents, and builds on positive Phase III results from Ascletis. If approved, the drug could address unmet need among approximately 10 million Americans.